Pfizer PFE Paxlovid and Comirnaty — Deferred revenue recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's paxlovid and comirnaty — deferred revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pfizer's paxlovid and comirnaty — deferred revenue recognized?
- Pfizer (PFE) reported paxlovid and comirnaty — deferred revenue recognized of $58M in Q1 2026.
- How has Pfizer's paxlovid and comirnaty — deferred revenue recognized changed year-over-year?
- Pfizer's paxlovid and comirnaty — deferred revenue recognized decreased by 82.7% year-over-year, from $335M to $58M.
- What does paxlovid and comirnaty — deferred revenue recognized mean?
- This represents the amount of previously deferred revenue that has been recognized in the income statement during the current period as performance obligations were satisfied. It quantifies the actual delivery and transfer of control of pharmaceutical products to customers. This metric is essential for reconciling cash receipts with actual revenue performance.